When drug companies apply for patents, the Patent and Trademark Office sometimes lacks critical information that the FDA already has — like details about a drug's approval history or labeling changes. This bill creates a formal task force between the two agencies so patent examiners can access FDA data when reviewing pharmaceutical patents. The goal is to prevent questionable patents that can be used to block cheaper generic drugs from reaching the market. It includes safeguards for confidential business information and requires a report to Congress within four years on how well the system is working.
Congressional Summary
Creates an interagency task force between the U.S. Patent and Trademark Office and the Food and Drug Administration to coordinate patent-related activities for drugs and biological products.
Legislative Subjects
Details
- Congress
- 119th
- Chamber
- Status
- summarized
- Action
- Action Date
- 2025-07-21
- Date Added
- 2026-03-31
- Source
- Congress.gov →
Like reading a bill in plain English?
We're building an app that does this for every bill in Congress and lets you tell your reps how you want them to vote. We're a small team getting ready to launch, and we're trying to show investors that real people want this. Be one of them. Help us get it built. Leave your email and we'll tell you the moment the app is ready.